Article ; Online: Inhibitory CARs fail to protect from immediate T cell cytotoxicity.
Molecular therapy : the journal of the American Society of Gene Therapy
2024 Volume 32, Issue 4, Page(s) 982–999
Abstract: ... proposed as strategy to increase on-tumor specificity of CAR-T cell therapies. iCARs inhibit T cell ... activation upon antigen recognition and thereby program a Boolean NOT gate within the CAR-T cell. If cancer ... coexpressing T cells are supposed to kill cancer cells but not healthy cells expressing the CAR antigen ...
Abstract | Chimeric antigen receptors (CARs) equipped with an inhibitory signaling domain (iCARs) have been proposed as strategy to increase on-tumor specificity of CAR-T cell therapies. iCARs inhibit T cell activation upon antigen recognition and thereby program a Boolean NOT gate within the CAR-T cell. If cancer cells do not express the iCAR target antigen while it is highly expressed on healthy tissue, CAR/iCAR coexpressing T cells are supposed to kill cancer cells but not healthy cells expressing the CAR antigen. In this study, we employed a well-established reporter cell system to demonstrate high potency of iCAR constructs harboring BTLA-derived signaling domains. We then created CAR/iCAR combinations for the clinically relevant antigen pairs B7-H3/CD45 and CD123/CD19 and show potent reporter cell suppression by iCARs targeting CD45 or CD19. In primary human T cells αCD19-iCARs were capable of suppressing T cell proliferation and cytokine production. Surprisingly, the iCAR failed to veto immediate CAR-mediated cytotoxicity. Likewise, T cells overexpressing PD-1 or BTLA did not show impaired cytotoxicity toward ligand-expressing target cells, indicating that inhibitory signaling by these receptors does not mediate protection against cytotoxicity by CAR-T cells. Future approaches employing iCAR-equipped CAR-T cells for cancer therapy should therefore monitor off-tumor reactivity and potential CAR/iCAR-T cell dysfunction. |
---|---|
MeSH term(s) | Humans ; T-Lymphocytes ; Receptors, Chimeric Antigen/genetics ; Iron-Dextran Complex ; Immunotherapy, Adoptive ; Neoplasms/therapy ; Cell Line, Tumor |
Chemical Substances | Receptors, Chimeric Antigen ; Iron-Dextran Complex (9004-66-4) |
Language | English |
Publishing date | 2024-02-22 |
Publishing country | United States |
Document type | Journal Article |
ZDB-ID | 2010592-7 |
ISSN | 1525-0024 ; 1525-0016 |
ISSN (online) | 1525-0024 |
ISSN | 1525-0016 |
DOI | 10.1016/j.ymthe.2024.02.022 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5640: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.